Hypotheses in non-inferiority trials [Power / Sample Size]

posted by mittyri  – Russia, 2015-06-16 23:52 (3556 d 07:00 ago) – Posting: # 14962
Views: 9,729

Hi Outlaw Torn

❝ What I'm getting at is this. When conducting a non-inferiority trial, are the roles of the type-I and type-II error rate reversed since the null hypothesis and the alternative hypothesis are reversed (Null Hypothesis H0 states non non-inferiority (i.e. inferiority) while Alternative Hypothesis H1 states non-inferiority between Test and Reference products)?


Let me cite Emmanuel Lesaffre:
"Demonstrating non-inferiority necessitates rejecting the null hypothesis (H0: ∆ > ∆NI) in favor of the alternative hypothesis (HA: ∆ < ∆NI) with an adapted classical statistical test (as for an equivalence test). A significant result (p < 0.025) means, in this case, that the experi­mental treatment is not (much) worse, i.e., non-inferior, to the control treatment, whereby the conclusion “non-inferior” depends on the chosen value for ∆NI."
I highly recommend you to read his great article (for me it's the best one). I think the relationships between equivalence, non-inferiority and superiority will be more clear.

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,406 posts in 4,919 threads, 1,743 registered users;
41 visitors (0 registered, 41 guests [including 7 identified bots]).
Forum time: 05:52 CET (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5